百济神州(06160)发布公告，于2026年1月23日，董事会薪酬委员会根据2016期权及激励计划的条款向二 百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。 ...

智通财经APP讯，百济神州(06160)发布公告，于2026年1月23 日，董事会薪酬委员会根据2016期权及激 励计划的条款向二百四十六名承授人授出涉及合共2.1万股美国存托股份的受限制股份单位。 ...

| | 2022年 | 2023年 | 2024年 | 2025年H | | --- | --- | --- | --- | --- | | 信达生物营业收入(亿元) | 45. 56 | 62.06 | 94. 22 | 59. 53 | | 销售开支 | 25.91 | 31.01 | 43. 47 | 23.75 | | 行政开支 | 8.35 | 7.5 | 7.38 | | | 研发开支(亿元) | 28. 71 | 22.28 | 26.81 | | | 信达生物归母净利润 | -21.79 | -10.28 | -0.9463 | 8.34 | | 最高市值 | 858.83 | 864.03 | 904.80 | 1892.89 | | 最低市值 | 322.71 | 473.66 | 491.01 | 497.08 | | 股本数(亿) | 17.35 | 17.35 | 17.35 | 17.35 | | 股价最高 | 49.5 | 49.8 | 52.15 | 109.1 | | 股价最低 | 18.6 | 27.3 | 28.3 | 28.65 | 来源：理忱视野 在《从Biotech ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2026年1月23 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百四十六名承授人授 出涉及合共21,034股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2026年1月23日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 四十六名承授人合共21,034股美國存託股份受限制股份單位。該等受限制股份單 位相當於273,442股股份，約佔本公告之日公司發行股份總數的0.02%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2026年1月23日 承授人數目： 二百四十六名 已授出受限制股份單位涉及的 相關股份數目： 273,44 ...

Core Insights - BeOne Medicines Ltd. (NASDAQ:ONC) is recognized as one of the top high-growth European stocks to invest in, with a Market Outperform rating and a price target of $396 set by Citizens due to strong Phase 3 trial results in gastric cancer patients [1] - The HERIZON-GEA-01 trial demonstrated high efficacy in patients with advanced gastric or gastroesophageal adenocarcinoma (GEA), further supporting the company's growth potential [1] - BeOne's Brukinsa is projected to generate approximately $3.8 billion in revenue by 2025, bolstered by a robust development pipeline across various indications [2] - The company has achieved its first clearance for sonrotoclax, a next-generation BCL2 inhibitor, which is expected to lead to further approvals globally [2] - BeOne maintains a strong cash position of $4.1 billion, and the recent decline in share price is viewed as a "unique buying opportunity" in the hematology/oncology sector [3] - BeOne Medicines Ltd. specializes in oncology medicines, focusing on treatments for blood cancers and solid tumors [3]

Group 1 - The technology sector experienced fluctuations in early trading due to the overnight decline in US stocks, while the AI industry chain showed resilience with a low rebound [1] - Alibaba is considering increasing its investment in AI infrastructure and cloud computing from 380 billion to 480 billion yuan over the next three years [1] - ByteDance plans to launch the official version of its Doubao mobile assistant by the end of 2025, with a new device expected to be released in late Q2 2026 [1] Group 2 - Microsoft and Meta reported that the tight supply of AI computing power will persist through 2026, with both companies exceeding market expectations for Q4 capital expenditures: Microsoft at 37.5 billion and Meta at 22.137 billion [1] - Meta has raised its full-year capital expenditure forecast for 2026 to 125 billion, a 73% year-on-year increase [1] - Research institutions predict that the demand for computing power will continue to rise in the next 3-6 months due to the intensive catalysts from AI applications and ongoing model iterations [1] Group 3 - As of January 30, 2026, the Shanghai Stock Exchange Science and Technology Innovation Board 100 Index showed mixed performance among its constituent stocks, with Shijia Photon leading at an increase of 8.56% [1] - The Science and Technology Innovation Board 100 ETF (588220) was quoted at 1.55 yuan [1] - The Science and Technology Innovation Board 100 ETF has a turnover rate of 4.66% and a transaction volume of 492 million yuan during the trading session [2]

Summary of Key Points from the Conference Call Industry Overview - The overall positioning of the pharmaceutical industry in 2026 is "innovation first, with drugs and devices flying together," indicating a more diversified market compared to 2025 [2] - The investment in innovative drugs requires careful selection, with the current market conditions presenting a good opportunity for entry after adjustments at the beginning of the year [3] Company Insights - Biofarma companies are highlighted as better investment choices due to their combination of R&D innovation, certainty, and long-term growth potential. The record-breaking BD amount in 2025 indicates a positive cycle of capital inflow into R&D [6] - Companies like 康方 (Kangfang), 百济神州 (BeiGene), and 英恩生物 (InnoCare) are expected to achieve commercial breakthroughs or expand internationally in the coming years [20] Market Trends - The global innovative drug development cycle is just beginning, with Chinese companies expected to account for 40% of transaction amounts by 2025, indicating a strong role in the global market [5] - The second-generation immune checkpoint inhibitors (IO) market is projected to reach $120 billion within the next decade, with significant participation from Chinese innovative drugs [12] Technological Advancements - Emerging technologies such as small nucleic acid therapies, molecular glue, gene editing, and long-acting drugs are expected to see significant development in 2026 [11][18] - Dual-specific antibodies and antibody-drug conjugates (ADC) are highlighted as promising treatment options for various cancers, including triple-negative breast cancer and small cell lung cancer [16][14] Policy and Regulatory Environment - The Chinese healthcare negotiation supports emerging therapies, including ADCs and siRNA, which are included in the healthcare directory, promoting self-sustaining funding and attracting more investors [7] Investment Opportunities - The report emphasizes the importance of focusing on companies with clear growth potential and stable revenue expectations, particularly those with significant upcoming data releases [26] - Notable companies to watch include 康诺亚 (Conway), 康弘 (Kanghong), and 毕比特 (BIBIT), which are considered to have strong upside potential [24] Conclusion - The future growth of companies in the pharmaceutical sector will rely on their global ecosystem platforms and the continuous iteration of their pipeline priorities, with a focus on high-potential projects [22]

Market Overview - The Hang Seng Index (HSI) closed at 27,742.89, down by 225.20 points or 0.81% as of January 29, 16:00 Eastern Time [1] - The index reached a high of 27,909.81 and a low of 27,419.65 during the trading session, with an average price of 27,664.73 [1] - The 52-week high for the index is 27,909.81, while the 52-week low is 19,335.70 [1] Blue-Chip Stocks Performance - Most large-cap stocks experienced declines, with HSBC Holdings closing at HKD 138.219, up 0.45% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 619.286, down 0.44% from the Hong Kong close [2] Individual Stock Movements - Tencent Holdings (00700) latest price is HKD 622.000, with a slight increase of 1.000 or 0.16% [3] - Alibaba Group (09988) latest price is HKD 173.300, down by 0.200 or 0.12% [3] - HSBC Holdings (00005) latest price is HKD 137.600, up by 0.100 or 0.07% [3] - China Construction Bank (00939) latest price is HKD 8.160, up by 0.130 or 1.62% [3] - AIA Group (01299) latest price is HKD 90.950, up by 2.100 or 2.36% [3] - Xiaomi Group (01810) latest price is HKD 36.620, up by 0.300 or 0.83% [3] - NetEase (099999) latest price is HKD 206.600, down by 5.400 or 2.55% [3] - Meituan (03690) latest price is HKD 98.600, up by 0.250 or 0.25% [3] - Industrial and Commercial Bank of China (01398) latest price is HKD 6.640, up by 0.050 or 0.76% [3] - Hong Kong Exchanges and Clearing (00388) latest price is HKD 444.200, up by 5.000 or 1.14% [3] - Ping An Insurance (02318) latest price is HKD 73.300, up by 2.350 or 3.31% [3] - Baidu Group (09888) latest price is HKD 155.500, down by 0.600 or 0.38% [3] - China Bank (03988) latest price is HKD 4.760, up by 0.090 or 1.93% [3] - BYD Company (01211) latest price is HKD 101.800, down by 1.000 or 0.97% [3] - JD.com (09618) latest price is HKD 114.600, down by 1.700 or 1.46% [3] - Ctrip Group (09961) latest price is HKD 482.200, down by 13.200 or 2.66% [3]

近日，新修订的《中华人民共和国药品管理法实施条例》（以下简称"新《条例》"）正式公布，自2026 年5月15日起施行。 作为我国药品监管体系的重要配套法规，新《条例》从药品研制、生产、经营到使用和监管全链条作出 系统性优化，尤其强化了对中药、儿童用药、罕见病用药等领域的规范管理。 多位受访专家对记者表示，此次修订将为创新药产业注入强劲政策动能。 新药上市周期缩短 2020年发布实施的《药品注册管理办法》，首次设立突破性治疗药物、附条件批准、优先审评审批和特 别审批这4个药品上市加快通道，新《条例》进一步将这4条通道写入法条。国家药监局数据显示，截至 2025年12月份，已有395个品种纳入突破性治疗药物程序，158个通过附条件批准上市，508个品种进入 优先审评通道。创新药平均审评时限较2018年缩短25%。 "这相当于把过去'试点性'的审评改革成果制度化、法治化。"中国企业联合会特约研究员胡麒牧对《证 券日报》记者表示，企业可以更稳定地规划研发管线，投资者也能获得更清晰的政策预期。 以恒瑞医药为例，其自主研发的PD-1抑制剂卡瑞利珠单抗已通过优先审评获批多个适应症；百济神州 的泽布替尼凭借突破性疗法认定加速 ...

Group 1 - The core point of the article highlights the acceleration of domestic pharmaceutical mergers and acquisitions (M&A), with companies like Kanghua Biotech and China Biopharmaceutical leading the trend [1][5][8] - Kanghua Biotech announced its acquisition of Nameixin through capital increase and equity transfer, marking a significant move in the domestic M&A landscape [1] - The trend of M&A in China's innovative drug sector is seen as a response to the need for companies to enhance their capabilities and integrate resources [5][7] Group 2 - Historically, M&A activities in China's innovative drug sector have been limited due to various factors, including the ambition of biotech companies to grow independently and the insufficient quality of innovations [4][3] - The financial strength of domestic pharmaceutical companies is relatively lower compared to their international counterparts, with leading domestic firms holding around $20 billion in cash compared to over $300 billion for top global firms [4] - Recent M&A activities, although smaller in scale compared to international deals, indicate a shift towards realizing the value of existing capabilities within leading domestic companies [5][6] Group 3 - The M&A trend is driven by the need for domestic companies to leverage their clinical development and commercialization capabilities, as seen in the case of Kanghua Biotech and Nameixin [6][7] - The integration of resources through M&A is expected to enhance the competitive edge of domestic firms, allowing them to quickly fill technological gaps and expand their product pipelines [8][9] - The acceleration of internal circulation in the industry is anticipated to create a more favorable ecosystem for both large pharmaceutical companies and smaller biotech firms, fostering innovation and addressing unmet clinical needs [9][10]